SOMAI PRO Technology is a proprietary AI-based drug discovery technology of SOM Biotech. It is based on Artificial Intelligence and operates by the identification of Molecular field maps.
SOM Biotech is an AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
We develop drugs for Orphan diseases for our internal pipeline but also develop strategic partnerships with major research centers and pharmaceutical companies, using AI to accelerate and boost their drug discovery process.
Clinically validated AI drug discovery and development technology
Although it is hard to find clinically-validated AI drug discovery technology, two SOM Biotech programmes have positive Clinical Phase 2a results. Clinical development of those programmes allowed to SOM Biotech to have the AI drug discovery technology with proof-of-concept.
Besides, the company has four programmes at the pre-clinical stage of development, and 20 projects at an early stage. All those programmes were obtained through our AI-based drug discovery technology.
AI in Drug Discovery and Development
Through our unique computational technology SOMAI PRO, we can efficiently apply AI in Drug Discovery and Development.
We utilise an exclusive approach uniting efficient computational algorithms with thorough analysis and design carried out by our experts in biochemistry, molecular biology and computational chemistry. This allows us to acquire an extensive list of high-grade lead candidate targets and hits.
The entire procedure is shorter, cheaper and more efficient in comparison to a typical research and development (R&D) process, and because of the individual approach, it can be applied to multiple therapeutic areas. The technology and our work process are authenticated by a pipeline of SOM Biotech and our partners’ projects.
Identifying drugs to treat specific diseases
We successfully apply SOMAI PRO technology to identify medicines for the treatment of a specific disease, as well as to discover new mechanisms of action and applications for a drug.
The primary strength of our AI technology is that it identifies new mechanisms of action (biological activity) of molecules, determining its non-structural analogues with similar biological activity.
The process allows us to identify effective drugs for the treatment of diseases, as well as new applications for drugs with a high likelihood of success and reliable patent protection. This is a principal differentiating factor concerning most AI-based approaches that use methods based on data mining, structural similarity, or target structure.
AI drug discovery technology applied for any therapeutic area
Although for our pipeline, we have focused our activities on accelerated discovery of drugs to treat orphan diseases, with our partners, we work with different therapeutic areas for drug discovery. As an AI drug discovery technology with Proof-of-concept, SOMAI PRO suits applications to any therapeutic area and new chemical entities.
Specifically, the latter is a clear competitive advantage, which will enable us to use AI to accelerate and boost drug discovery.
We aim to develop value, creating partnerships with strategic partners to leverage the intrinsic potential of SOMAI PRO to discover treatments to tackle some of the most acute diseases.
Outstanding developmental team that achieves high-quality results
SOM Biotech’s development unit works alongside the company’s computational chemists to plan screening procedures in line with the particularity of every project.
The teams outline and enhance each parameter essential for effective project performance, accurately selecting the most suitable information used in the process.
As a result of the design, we can recover high-quality information from extensive databases, continuing to fast-track the drug discovery process and transform the current R&D model.
AI drug discovery technology with experimental validation
SOM Biotech completes comprehensive experimental validation of acquired data from medical and scientific standpoints, as well as from business perspectives.
For investigational authentication, our preclinical and clinical teams plan each experiment required to analyse specific molecules. Throughout the process, we use our team’s expertise and diverse profiles, as well as the estimation of key opinion leaders in each area
SOM3355 successfully finished Clinical Phase 2a PoC. SOM3355 is the only safe VMAT2(-) not related to serious adverse events like depression, suicide, parkinsonism or neuroleptic syndrome.
Unique advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological activity defined by Molecular Field Maps, which were not described before and non-structural analogues identification reliable patent protection.
SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment of diseases with a high unmet need, announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020 (21-25 October).
SOM Biotech Announces in Vitro Confirmation of Drug Candidates for Covid-19 in Collaboration with Ewha Woman’s University
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of three drug candidates as new therapies for the treatment of Covid-19.
SOM Biotech has made Sifted's list as one of the Top Spanish Start-ups to follow in 2020.